National Drug Formulary review of statin therapeutic group using the multiattribute scoring tool

References

• American Society of Hospital PharmacistsASHP guidelines on formulary system managementAm J Hosp Pharm19924936486521598948
   PubMedGoogle Scholar
• Pharmaceutical Services Division Ministry of Health MalaysiaPanduan Kepada Formulari Ubat KKM (Guidelines to the MOH Drug Formulary)2nd edPharmaceutical Services Division Ministry of Health MalaysiaPetaling Jaya, Malaysia2007115
   Google Scholar
• ScottMJanknegtRBrenninkmeijerRA prelude to the Matrix Models SupplementExpert Opin Pharmacother200781S1S417931074
   PubMed Web of Science ®Google Scholar
• DyerJSFishburnPCSteuerREMultiple criteria decision making, multiattribute utility theory: the next ten yearsManagement Science1992385645654
   Web of Science ®Google Scholar
• Department for Communities and Local Government LMulti-criteria Analysis: A ManualLondonCrown20091168
   Google Scholar
• ZachryWMSkrepnekGHPractical pharmacoeconomics: applying multiattribute utility technology to the formulary evaluation processFormulary200237April199206
   Google Scholar
• BaltussenRNiessenLPriority setting of health interventions: the need for multi-criteria decision analysisCost Effectiveness and Resource Allocation20064141916412255
   PubMedGoogle Scholar
• ChungSKimSKimJSohnKUse of multiattribute utility theory for formulary management in a health systemAmerican J Health-Syst Pharm2010672128135
   PubMed Web of Science ®Google Scholar
• JanknegtRTriptans in the treatment of migraine: drug selection by means of the SOJA methodExpert Opin Pharmacother20078Suppl 1S15S3017931075
   PubMed Web of Science ®Google Scholar
• YoungkongSTeerawattananonYTantivessSBaltussenRMulti-criteria decision analysis for setting priorities on HIV/AIDS interventions in ThailandHealth Research Policy and Systems/BioMed Central20121012822280794
   PubMed Web of Science ®Google Scholar
• GoetghebeurMMWagnerMKhouryHLevittRJEricksonLJRindressDEvidence and Value: Impact on DEcisionMaking – the EVIDEM framework and potential applicationsBMC Health Services Research2008827011618173837
   PubMed Web of Science ®Google Scholar
• JanknegtRScottMMairsJTimoneyMMcElnayJSystem of Objectified Judgement Analysis (SOJA) as a tool in rational and transparent drug-decision makingExpert Opin Pharmacother20078Suppl 1S5S1417931079
   PubMed Web of Science ®Google Scholar
• AlabbadiICrealeyGScottMImpact of Modified System of Objectified Judgement Analysis (SOJA) methodology on prescribing costs of ACE inhibitorsClin. Drug Invest2006269485494
   PubMed Web of Science ®Google Scholar
• ChongtrakulPSumpraditNYoongthongWISafE and the evidence-based approach for essential medicines selection in ThailandEssential Drugs Monitor2005341819
   Google Scholar
• Pharmaceutical Services Division and Clinical Research Centre M of HMMalaysian Statistics on Medicines 2008Kuala Lumpur20131176
   Google Scholar
• ClausonKMarshWPolenHHSeamonMJOrtizBIClinical decision support tools: analysis of online drug information databasesBMC Medical Informatics and Decision Making200771717214888
   PubMed Web of Science ®Google Scholar
• MooreAPWheeldonNMJenningsMA formulary analysis of angiotensin II antagonists in a UK teaching hospitalDisease Management and Health Outcomes2002106355362
   Google Scholar
• World Health Organization (WHO) [homepage on the internet]WHO Collaborating Centre for Drug Statistics Methodology, Oslo2012 Available at: http://www.whocc.no/atc_ddd_index/Accessed February 19, 2012
   Google Scholar
• GrundySMCleemanJIMerzCNBImplications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesJournal of the American College of Cardiology2004443720732. 315358046
   PubMedGoogle Scholar
• Micromedex® Healthcare Series (database on CD-ROM)Thomson ReutersGreenwood, Village, CO, USA15262012
   Google Scholar
• TrialResults-centre FranceTrialresultscenter.org [homepage on the internet] Available at: http://www.trialresultscenter.org/sNb.aspAccessed February 22, 2012
   Google Scholar
• TranYFrialTMillerPStatin’s cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statinsCan J Clin Pharmacol2007142e205e21417556788
   PubMedGoogle Scholar
• JonesPHDavidsonMHSteinEComparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)The American Journal of Cardiology200393215216012860216
   PubMed Web of Science ®Google Scholar
• KapurNKMusunuruKClinical efficacy and safety of statins in managing cardiovascular riskVascular Health and Risk Management20084234135318561510
   PubMedGoogle Scholar
• EdwardsJEMooreRAStatins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trialsBMC Fam Pract200341814969594
   PubMedGoogle Scholar
• Hippisley-CoxJCaterRPringleMCouplandCCross sectional survey on effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practicesBMJ200332668912663406
   PubMed Web of Science ®Google Scholar
• OngHEvidence-based prescribing of statins: a developing world perspectivePLoS Medicine200633e50 Available at: http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.0030050Accessed July 22, 201316478294
   PubMed Web of Science ®Google Scholar
• WebMDLLDNew York. Reference.medscape.com Available at: http://reference.medscape.com/pharmacistsAccessed March 22, 2012
   Google Scholar
• US National Library of Medicines, National Institute of HealthPubmed. gov [homepage on the internet] Available at: http://www.ncbi.nlm.nih.gov/pubmedAccessed March 2, 2012
   Google Scholar
• ClaxtonAJCramerJPierceCA systematic review of the associations between dose regimens and medication complianceClinical Therapeutics20012381296131011558866
   PubMed Web of Science ®Google Scholar
• SchiffGDGalanterWLDuhigJA prescription for improving drug formulary decision makingPLoS Medicine2012951722629233
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP)JAMA2001285192486249711368702
   PubMed Web of Science ®Google Scholar
• NeuvonenPJNiemiMBackmanJTDrug interactions with lipid- lowering drugs: mechanisms and clinical relevanceClinical Pharmacology and Therapeutics200680656558117178259
   PubMed Web of Science ®Google Scholar
• HatanakaTClinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic eventsClin Pharmakokinetics2000396397412
   PubMed Web of Science ®Google Scholar
• AstraZeneca PharmaceuticalsFull Prescribing Information: Rosuvatatin Calcium (R)201319
   Google Scholar
• DavidsonMHClarkJAGlassLMKanumallaAStatin safety: an appraisal from the adverse event reporting systemAm J Cardiol2006978A32C43C
   PubMed Web of Science ®Google Scholar
• FlorentinusSRHeerdinkERKlungelOHde BoerAShould rosuvastatin be withdrawn from the market?Lancet200436494451577 author reply 1578–157915519621
   PubMed Web of Science ®Google Scholar
• SilvaMASwansonACGandhiPJTataronisGRStatin-related adverse events: a meta-analysisClinical Therapeutics2006281263516490577
   PubMed Web of Science ®Google Scholar
• NakamuraHArakawaKItakuraHPrimary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trialLancet200636895421155116317011942
   PubMed Web of Science ®Google Scholar
• ShepherdJBlauwGMurphyMPravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialThe Lancet2002 Available at: http://www.sciencedirect.com/science/article/pii/S014067360211600XAccessed July 22, 2013
   Web of Science ®Google Scholar
• Heart Protection Study Collaborative GroupArticles MRC / BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trialLancet2002360July 672212114036
   PubMed Web of Science ®Google Scholar
• DownsJRClearfieldMWeisSPrimary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. [Abstract]JAMA199827920161516229613910
   PubMed Web of Science ®Google Scholar
• AmarencoPBogousslavskyJCallahanAHigh-dose atorvastatin after stroke or transient ischemic attackNew Engl J Med2006355654955916899775
   PubMed Web of Science ®Google Scholar
• ColhounHMBetteridgeDJDurringtonPNPrimary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialLancet2004364943568569615325833
   PubMed Web of Science ®Google Scholar
• KjekshusJApetreiEBarriosVRosuvastatin in older patients with systolic heart failureNew Engl J Med2007357222248226117984166
   PubMed Web of Science ®Google Scholar
• RidkerPMDanielsonEFonsecaFAHRosuvastatin to prevent vascular events in men and women with elevated C-reactive proteinNew Engl J Med2008359212195220718997196
   PubMed Web of Science ®Google Scholar
• AnderssenSAHjelstuenAKHjermannIBjerkanKHolmeIFluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensivesAtherosclerosis2005178238739715694949
   PubMed Web of Science ®Google Scholar